妊娠期疟疾的预防
妊娠期疟疾是可预防的不良出生结局原因之一。综述汇总了间歇性预防治疗(IPTp)方案的证据:磺胺多辛-乙胺嘧啶在非洲部分高耐药地区仍与低出生体重减少相关,但六重突变虫株感染时疗效受损;六项试验显示阿莫地喹、甲氟喹、氯喹-阿奇霉素因耐受性差不宜替代;四项试验显示间歇筛查与治疗不适宜替代IPTp;两项试验显示双氢青蒿素-哌喹耐受性好、有效且可接受,每月方案最有效。
要点
- 非洲荟萃分析显示三疗程或每月磺胺多辛-乙胺嘧啶IPTp安全且优于原两疗程策略,WHO于2012年更新政策。
- 磺胺多辛-乙胺嘧啶耐药降低寄生虫学疗效,但在五重突变流行率大于90%地区仍与低出生体重减少相关。
- 双氢青蒿素-哌喹IPTp耐受性好、有效且可接受,每月方案最有效,但需确认性试验。
核心结论
- 磺胺多辛-乙胺嘧啶IPTp仍是非洲部分地区的预防策略,但耐药影响疗效,需要新替代方案。
- 双氢青蒿素-哌喹IPTp显示良好前景,但需确认性试验评估安全性、有效性和可行性。
研究设计与样本
- 综述汇总了非洲及其他地区关于妊娠期疟疾预防的临床试验、荟萃分析和建模分析证据。
主要发现
- 非洲荟萃分析显示三疗程或每月磺胺多辛-乙胺嘧啶IPTp安全且比原两疗程策略更有效。
- 磺胺多辛-乙胺嘧啶在五重突变流行率大于90%地区仍与低出生体重减少相关,但六重突变虫株感染时疗效受损。
- 六项IPTp试验显示阿莫地喹、甲氟喹、氯喹-阿奇霉素因耐受性差均不适宜替代磺胺多辛-乙胺嘧啶。
- 四项试验显示当前一代疟疾快速诊断试验的间歇筛查与治疗即使在高五重突变流行区也不适宜替代磺胺多辛-乙胺嘧啶IPTp。
- 两项试验显示双氢青蒿素-哌喹IPTp耐受性好、有效且可接受,每月方案最有效;巴布亚新几内亚单试验提示磺胺多辛-乙胺嘧啶联合阿奇霉素整合方案可能作用。
临床怎么用
- WHO于2012年更新政策,推荐三疗程或每月磺胺多辛-乙胺嘧啶IPTp,而非原两疗程策略。
- IPTp和杀虫剂处理蚊帐覆盖率仍落后于目标,关键障碍已有记录且许多可干预。
局限性
- 磺胺多辛-乙胺嘧啶耐药降低IPTp寄生虫学疗效,六重突变虫株感染时 effectiveness 受损。
- 阿莫地喹、甲氟喹、氯喹-阿奇霉素因耐受性差不宜替代。
- 当前一代快速诊断试验的间歇筛查与治疗不适宜替代IPTp。
- 巴布亚新几内亚证据仅来自单项试验。
- 需双氢青蒿素-哌喹IPTp确认性试验及更敏感快速诊断试验、整合策略、HIV阳性非洲以外孕妇预防策略研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malaria remains one of the most preventable causes of adverse birth outcomes. Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine is used to prevent malaria, but resistance to this drug combination has decreased its efficacy and new alternatives are needed. In Africa, a meta-analysis showed three-course or monthly IPTp with sulfadoxine-pyrimethamine to be safe and more effective than the original two-course sulfadoxine-pyrimethamine strategy, prompting WHO to update its policy in 2012. Although resistance to sulfadoxine-pyrimethamine reduces the parasitological efficacy of IPTp, this drug combination remains associated with reduced incidence of low birthweight in areas where prevalence of parasites with quintuple Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and dihydropteroate synthetase (Pfdhps) mutations is greater than 90%. Nevertheless, its effectiveness is compromised in women infected with sextuple mutant parasites. Six trials of IPTp showed that neither amodiaquine, mefloquine, nor chloroquine-azithromycin are suitable replacements for sulfadoxine-pyrimethamine because of poor tolerability. Furthermore, four trials showed that intermittent screening and treatment with the current generation of malaria rapid diagnostic tests was not a suitable alternative strategy to IPTp with sulfadoxine-pyrimethamine, even in areas with high prevalence of quintuple mutations. Two trials showed that IPTp with dihydroartemisinin-piperaquine was well tolerated, effective, and acceptable for IPTp, with monthly regimens being the most effective. Coverage of IPTp and insecticide-treated nets continues to lag behind targets. The key barriers to uptake are well documented, and many are open to intervention. Outside of Africa, a single trial suggests a potential role for integrated approaches that combine sulfadoxine-pyrimethamine with azithromycin for IPTp in areas of Papua New Guinea where malaria transmission is high. Modelling analysis suggests the importance of the prevention of malaria early in pregnancy and the need to protect pregnant women declines more slowly than the rate at which transmission declines. Improved funding has led to an increase in the number of prevention trials in the past decade, showing the value of more sustained protection with monthly IPTp regimens. There is a need for confirmatory trials of the safety, efficacy, and feasibility of IPTp with dihydroartemisinin-piperaquine, for studies of intermittent screening and treatment with more sensitive rapid diagnostic tests, for studies of integrated strategies for malaria and other co-infections, and for studies of prevention strategies for malaria in pregnant women who are HIV-positive and living outside of Africa. Additional research is required on how to improve uptake of WHO's updated policy on IPTp with sulfadoxine-pyrimethamine and insecticide-treated nets.
引用
- Desai M, Hill J, Fernandes S, et al. Prevention of malaria in pregnancy. Lancet Infect Dis. 2018. PMID: 29395997. doi:10.1016/S1473-3099(18)30064-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。